Business Wire

DS-8201 ([Fam-] Trastuzumab Deruxtecan) Achieved A Tumor Response Rate of 60.9% in Pivotal Phase 2 HER2 Positive Metastatic Breast Cancer Trial

Share

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today presented positive detailed data from the global pivotal phase 2 single-arm DESTINY-Breast01 trial of DS-8201 ([fam-] trastuzumab deruxtecan), an investigational HER2 targeting antibody drug conjugate (ADC), in patients with HER2 positive metastatic breast cancer. The data were part of the press program at the 2019 San Antonio Breast Cancer Symposium (#SABCS19) and simultaneously published online in The New England Journal of Medicine.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191211005272/en/

Daiichi Sankyo and Astra Zeneca DS-8201 Joint Executive Committee (JEC) Global Business Leadership - Left to Right: Dave Frederickson, Executive Vice President, Global Head Oncology Business Unit, AstraZeneca; Shoji Hirashima, PhD, Executive Officer, Head of Global Brand Strategy Division, DS-8201 Global Business Head, Daiichi Sankyo (Photo: Business Wire)

Daiichi Sankyo and Astra Zeneca DS-8201 Joint Executive Committee (JEC) Global Business Leadership - Left to Right: Dave Frederickson, Executive Vice President, Global Head Oncology Business Unit, AstraZeneca; Shoji Hirashima, PhD, Executive Officer, Head of Global Brand Strategy Division, DS-8201 Global Business Head, Daiichi Sankyo (Photo: Business Wire)

The primary endpoint of objective response rate (ORR), confirmed by independent central review, was 60.9% with DS-8201 monotherapy (5.4mg/kg) in patients with HER2 positive metastatic breast cancer who received two or more prior HER2 targeted regimens. Patients achieved a disease control rate (DCR) of 97.3% with a median duration of response (DOR) of 14.8 months (range 13.8 - 16.9) and median progression-free survival of 16.4 months (range 12.7 - not reached). The median overall survival (OS) has not yet been reached with an estimated survival rate for patients receiving DS-8201 of 86% at one year. The results were consistent across subgroups of patients.

Patients receiving DS-8201 in the DESTINY-Breast01 trial had a median of six prior regimens for metastatic disease (range 2 - 27), including ado-trastuzumab emtansine (T-DM1) (100%), trastuzumab (100%), pertuzumab (65.8%), other anti-HER2 therapies (54.3%), hormone therapies (48.9%), and other systemic therapies (99.5%). Median treatment duration for DS-8201 was 10 months (range: 0.7 - 20.5 months) with a median duration of follow-up of 11.1 months (range: 0.7 - 19.9). As of data cut-off on August 1, 2019, 42.9% of patients remained on-treatment.

The safety and tolerability profile of DS-8201 in DESTINY-Breast01 was consistent with that observed in the phase 1 trial. The most common grade 3 or higher treatment emergent adverse events were decreased neutrophil count (20.7%), anemia (8.7%), nausea (7.6%), decreased white blood cell count (6.5%), decreased lymphocyte count (6.5%) and fatigue (6%). Overall, 13.6% of patients had confirmed interstitial lung disease (ILD) related to treatment as determined by an independent review. The events were primarily grade 1 or 2 (10.9%) in severity with one grade 3 (0.5%) and no grade 4 events. Four deaths (2.2%) were determined to be due to ILD.

Regulatory submission of DS-8201 for the treatment of patients with HER2 positive metastatic breast cancer was recently accepted with Priority Review by the U.S. Food and Drug Administration (FDA). A regulatory submission also has been made to Japan’s Ministry of Health, Labour and Welfare (MHLW).

“These results are particularly striking as DS-8201 prompted a high level of durable tumor reduction among patients, the majority of whom had exhausted most, if not all, standard therapies for the treatment of HER2 metastatic breast cancer,” said Ian E. Krop, MD, PhD, Associate Chief, Division of Breast Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute. “We are excited by these results and their potential to help patients with this advanced stage of breast cancer.”

“The strength of the pivotal results and the consistency with previously reported DS-8201 data further underscore that this specifically engineered HER2 targeted antibody drug conjugate is delivering on its intent of enhancing efficacy for patients with HER2 positive metastatic breast cancer,” said Antoine Yver, MD, MSc, Executive Vice President and Global Head, Oncology Research and Development, Daiichi Sankyo.

“The clinically meaningful and durable responses seen among these patients illustrate the potential of DS-8201 to establish a new standard of care,” said José Baselga, MD, PhD, Executive Vice President, R&D Oncology, AstraZeneca. “These results are impressive, as women with this advanced stage of breast cancer have already endured multiple prior therapies for HER2 positive metastatic breast cancer.”

Summary of Resultsi

Efficacy measure

Total evaluable (n=184)ii

ORR (%) (95% CI)

60.9 (53.4-68)

CR (%)iii

6.0

PR (%)iii

54.9

SD (%)iii

36.4

PD (%)

1.6

CBR (%)iv

76.1 (69.3-82.1)

Median DoR (95% CI)

14.8 months (13.8-16.9)

Median PFS (95% CI)

16.4 months (12.7-NE)

Median OS (95% CI)

NE (NE-NE)

Estimated OS at 12 months (%) (95% CI)

86 (80-91)

CI, confidence interval; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; CBR, clinical benefit rate; NE, not estimable
i As assessed by independent central review
ii 5.4 mg/kg
iii DCR is (CR + PR + SD) is 97.3% (95% CI, 93.8-99.1)
iv Responses lasting greater than six months

About HER2
HER2 is a tyrosine kinase receptor growth-promoting protein found on the surface of some cancer cells that is associated with aggressive disease and poor prognosis in patients with breast cancer.1 To be considered HER2 positive, tumor cancer cells are usually tested by one of two methods: immunohistochemistry (IHC) or fluorescent in situ hybridization (FISH). IHC test results are reported as: 0, IHC 1+, IHC 2+, or IHC 3+.2 A finding of IHC 3+ and/or FISH amplification is considered positive.2

About HER2 Positive Breast Cancer
Approximately one in five breast cancers are HER2 positive.2,3 Despite recent improvements and approvals of new medicines, there remain significant unmet needs for patients with advanced HER2 positive metastatic breast cancer.4,5 This disease remains incurable with patients eventually progressing after available treatment.4,5

About DESTINY-Breast01
DESTINY-Breast01 is a pivotal phase 2, single-arm, open-label, global, multicenter, two-part trial evaluating the safety and efficacy of DS-8201 in patients with HER2 positive unresectable and/or metastatic breast cancer previously treated with ado-trastuzumab emtansine. The primary endpoint of the trial is objective response rate, as determined by independent central review. Secondary objectives include, duration of response, disease control rate, clinical benefit rate, progression-free survival, and overall survival. Enrollment into DESTINY-Breast01 was completed in September 2018 with 253 patients at more than 100 sites across North America, Europe, Japan and other countries in Asia.

About DS-8201
DS-8201 (fam- trastuzumab deruxtecan in U.S. only; trastuzumab deruxtecan in other regions of world) is the lead product in the investigational ADC Franchise of the Daiichi Sankyo Cancer Enterprise and the most advanced program in AstraZeneca’s ADC scientific platform.

In March 2019, Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize DS-8201 as a potential new medicine worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo will be solely responsible for the manufacturing and supply.

A comprehensive development program for DS-8201 is underway globally with five pivotal trials in HER2 expressing metastatic breast and gastric cancer, including a trial in patients with metastatic breast cancer and low levels of HER2 expression (HER2 low). Phase 2 trials are underway for HER2 expressing advanced colorectal cancer as well as metastatic non-squamous HER2 overexpressing or HER2 mutated non-small cell lung cancer. Trials in combination with other anticancer treatments, such as immunotherapy, also are underway.

The U.S. Food and Drug Administration (FDA) recently granted Priority Review for the Biologics License Application (BLA) for DS-8201 for the treatment of HER2 metastatic breast cancer, which previously received Breakthrough Therapy and Fast Track Designation. A regulatory submission for DS-8201 also has been made to Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of HER2 positive metastatic breast cancer, and it has previously received SAKIGAKE designation for the treatment of advanced HER2 positive gastric or gastroesophageal junction cancer by Japan’s MHLW.

DS-8201 is an investigational agent that has not been approved for any indication in any country. Safety and efficacy have not been established.

About Daiichi Sankyo Cancer Enterprise
The mission of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do. Anchored by three pillars including our investigational Antibody Drug Conjugate Franchise, Acute Myeloid Leukemia Franchise and Breakthrough Science pipeline, we aim to deliver seven distinct new molecular entities over eight years during 2018 to 2025. Our powerful research engines include two laboratories for biologic/immuno-oncology and small molecules in Japan, and Plexxikon Inc., our small molecule structure-guided R&D center in Berkeley, CA. For more information, please visit: www.DSCancerEnterprise.com.

About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com.

References

1 American Cancer Society. Breast Cancer HER2 Status. Available at https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-her2-status.html. Accessed August 2019.
2 Tandon A, et al. HER-2/neu Oncogene Protein and Prognosis in Breast Cancer. J Clin Oncol. 1989;7(8):1120-8.
3 Sledge G, et al. Past, Present, and Future Challenges in Breast Cancer Treatment. J Clin Oncol. 2014;32(19):1979-1986.
4 de Melo Gagliato D, et al. Mechanisms of Resistance and Sensitivity to Anti-HER2 Therapies in HER2+ Breast Cancer. Oncotarget. 2016;7(39):64431-46.
5 National Comprehensive Cancer Network (NCCN). NCCN Guidelines. Breast Cancer. Available at https://nccn.org. Accessed August 2019.

Contact information

Media Contacts:

Global/US:
Jennifer Brennan
Daiichi Sankyo, Inc.
jbrennan2@dsi.com
+1 908 992 6631 (office)
+1 201 709 9309 (mobile)

EU:
Lydia Worms
Daiichi Sankyo Europe GmbH
lydia.worms@daiichi-sankyo.eu
+49 (89) 7808751

Japan:
Koji Ogiwara
Daiichi Sankyo, Co., Ltd
ogiwara.koji.ay@daiichisankyo.co.jp
+81 3 6225 1126 (office)

Investor Relations Contact:
DaiichiSankyoIR@daiichisankyo.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Science, Data, and Facts Should Unite Decision-Making, Says PMI CEO in Speech at Concordia Summit24.9.2020 22:20:00 EESTPress release

André Calantzopoulos, CEO of Philip Morris International (PMI) (NYSE: PM), today delivered high-level remarks at the 2020 Concordia Annual Summit. Calantzopoulos discussed the impact that uncertainty, polarization, hyperpartisanship, and ideology are having on international efforts to overcome pressing global issues. He called for science to be protected from politicization and highlighted the importance of developing open dialogues based on factual scientific objectivity. Calantzopoulos shared PMI’s belief that with the right regulatory encouragement and support from civil society, cigarette sales can end within 10 to 15 years in many countries. The Concordia Annual Summit, which coincides with the United Nations General Assembly (UNGA) meeting, convenes the world’s most prominent business, government, and nonprofit leaders to foster dialogue and enable effective partnerships for positive social impact. Excerpts of the remarks by André Calantzopoulos follow: “Reflecting on the state o

Swiss Medical Group Holding Acquires CoreMedica Europe24.9.2020 18:54:00 EESTPress release

Swiss Medical Group (SMG) Holding Luxembourg S.A., leading the development of STARKS Age-Management in Europe and Asia, announced today the acquisition of CoreMedica Europe, to expand in Europe and the rest of the world. CoreMedica Europe recently made the headlines in Switzerland for combining a COVID-19 Screening Test and Immunity profile with its existing home self-collection kit that allows customers to collect a few drops of blood and send them by mail to CoreMedica Europe’s accredited laboratory in Geneva to screen the anti-SARS-COV-2 IgG antibody and assess any previous infection to SARS-COV-2, the virus responsible for COVID disease, and analyze a set of 5 key biomarkers known to support the immune system (vitamin D, zinc, magnesium, copper, selenium) so as to receive personalized actionable recommendations to help patients build up their natural defenses against the effects of a next potential viral infection. “In this epidemic and containment context the essential objective

Esri and AfroChampions Launch Partnership to Promote GIS in Africa24.9.2020 16:52:00 EESTPress release

Esri, the global leader in location intelligence, today announced a joint initiative with AfroChampions, a Pan-African nonprofit that aims to promote policies that foster private-public collaboration for Africa's economic transformation. The goal of the initiative is to engage leaders in business, governments, the African Union, and other regional economic communities through dialogue and potential partnership building in applying geospatial technology and solutions. This new partnership with AfroChampions seeks to contribute to sustainable economic development in Africa and promote the benefits of a shared geospatial infrastructure throughout the continent. As a majority of Africans still live in rural areas, geographic information system (GIS) technology can create new opportunities for growth, especially in critical fields such as health and telemedicine, land management, agriculture, and mobility. The powerful mapping and data analytics that GIS provides forms a foundation for some

DXC Technology Announces Leadership Appointments to Support the “new DXC"24.9.2020 16:20:00 EESTPress release

DXC Technology (NYSE:DXC) today presented its latest leadership appointments further strengthening the DXC leadership team, the majority being new to DXC within the last year. This team is bringing the “new DXC,” which is focused on its customers and its people, to the market as it executes the company’s transformation journey. DXC Customer Portfolio Leadership Over the past year, CEO Mike Salvino has recruited new IT services industry leaders who bring formidable experience delivering for customers, inspiring people, and running and growing businesses. DXC announces the following appointments and changes to the team that will run DXC’s business and lead execution of the DXC transformation journey: Americas will be led by Jim Brady and David Swift . Jim joined DXC in June 2020 from Accumen, where he was the COO and previously worked at Accenture and Honeywell. David Swift joined DXC in November 2019 from Accolade where he was Chief Service Officer and previously worked at Aon Hewitt an

Statement on One-Year Anniversary of Women’s Entrepreneurship Accelerator24.9.2020 16:07:00 EESTPress release

Please find the statement below from Women’s Entrepreneurship Accelerator leadership regarding the one-year anniversary of the ground-breaking initiative. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200924005283/en/ Anita Bhatia, Deputy Executive Director, UN Women One year ago, we committed to educating and empowering ten million women entrepreneurs over the next ten years through the Women’s Entrepreneurship Accelerator (WEA). We began to lay the groundwork for a systemic transformation to break down the barriers keeping women from achieving financial independence and contributing to a better future for themselves and their communities. Today, in our unprecedented reality, women find themselves at history’s crossroads. They are disproportionately harmed by the economic devastation wrought by COVID-19 while simultaneously holding the keys to recovery. Women make up 39% of global employment but have accounted for 54% of o

Airship Acquires Conversational Commerce Pioneer ReplyBuy to Accelerate Expansion Into Mobile Commerce24.9.2020 16:00:00 EESTPress release

Customer engagement company Airship today announced that it has acquired ReplyBuy, a company that pioneered fully integrated solutions for payments over SMS. This move extends Airship’s platform beyond customer engagement to directly enable commerce, as well as power one-to-one customer conversations via two-way SMS. In addition, Airship plans to extend ReplyBuy’s technology to provide turnkey commerce and payments solutions across more marketing channels, messaging platforms and industry verticals. The acquisition will provide companies of all sizes a single platform to create, manage and optimize cross-channel customer interactions and drive greater revenue more quickly. Airship’s real-time mobile data, predictive AI and unified approach to customer journeys ensures relevant messaging at the optimal time on customers’ preferred channels across app and web notifications, SMS, email, mobile wallet and more. Subsequent digital actions customers take, now including purchases and conversa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom